Sucheta Dalal :Piramal looks at smaller labs for growth
Sucheta Dalal

Click here for FREE MEMBERSHIP to Moneylife Foundation which entitles you to:
• Access to information on investment issues

• Invitations to attend free workshops on financial literacy
• Grievance redressal


You are here: Home » What's New » Piramal looks at smaller labs for growth
                       Previous           Next

Piramal looks at smaller labs for growth  

March 22, 2010

Piramal Diagnostic Services Pvt Ltd (PDSL), the diagnostics service unit of Piramal Healthcare Ltd, is talking of acquiring small diagnostics labs across India in its quest for growth. However, the strategy of buying a large number of smaller players (called ‘roll-ups’ in the US) has not succeeded in India. PDSL may not be an exception. There are several problems with roll-ups in general and PDSL in particular.


The company made its last acquisitions in the year 2007-2008 and has been incurring heavy losses for the past three years. After that, the company has not shown any interest in expansion or acquisitions. In its annual report of 2007-2008, it had mentioned that it had acquired 16 new laboratories and completed a three-way merger between Rana Diagnostics, Dr Phadke’s Laboratories and PDSL.


PDSL thinks that there are 10 pathology labs across the country which fit in with its business model, and are ideal acquisitions to look at. It is betting at a minimum turnover of Rs5 crore through this route. Currently it has 135 service centres in the country. We will be surprised if the company succeeds in acquiring at least four out of these 10 that it is targeting.


“In the last two years, the company did not look at any acquisition because it wanted to consolidate its diagnostics business. It is now focusing on buying regional players,” said Sapna Jhawar, research analyst (pharmaceuticals), ShareKhan. “Currently, the company has acquired 20 path labs across the country. In the last two years, the company has not shown keen interest in buying the path labs. Ten is a big number for the company,” she added.


It may be recalled that Piramal tried to acquire Dr Lal’s Path Labs some years back but the deal did not work out. Indeed, Metropolis, the fastest-growing player in the diagnostics segment, is growing by continuously setting up its own laboratories in different parts of the country and even overseas. Metropolis started its operations in 1981 and has 50 plus state of–the-art laboratories across the globe. It is present in places like the UAE, Seychelles, Sri Lanka, Thailand and South Africa. According to various media reports, it is planning to add five more labs this year. Although it recently acquired a majority stake in Bengaluru-based RV Diagnostic Laboratory, Metropolis has grown primarily through its own new labs. It has made only 12 acquisitions in the past five years including a recent one.


There are several reasons roll-ups don’t work in India. First, there are often no sellers. A large nationwide player may believe that it has to only dangle cash in front of tiny players but very often, the tiny player may simply not like to sell out, because the business is not just a question of money but a life occupation.


Second, when a bigger player is looking at buying out a smaller unit, the cost of the property is also a major factor. A more preferred route is a franchise model, but that will yield lower profits for the bigger player.


Interestingly, while PDSL is talking of acquisitions, the business is running at large losses for the last three years. The losses it has incurred over the past three years were Rs3.54 crore (2007), which increased to Rs4.20 crore and Rs3.71 crore in 2008 and 2009, respectively. — Pallabika Ganguly


-- Sucheta Dalal